ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.07 CNY | +2.87% |
|
-6.05% | -40.60% |
| Sales 2022 | 531M 73.24M | Sales 2023 | 520M 71.63M | Capitalization | 3.67B 506M |
|---|---|---|---|---|---|
| Net income 2022 | 44M 6.07M | Net income 2023 | -8M -1.1M | EV / Sales 2022 | 7.05 x |
| Net Debt 2022 | 156M 21.56M | Net cash position 2023 | 140M 19.37M | EV / Sales 2023 | 6.8 x |
| P/E ratio 2022 |
80
x | P/E ratio 2023 |
-423
x | Employees | 1,159 |
| Yield 2022 * |
-
| Yield 2023 |
0.99% | Free-Float | 24.95% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.87% | ||
| 1 week | -6.05% | ||
| Current month | -7.83% | ||
| 1 month | -19.15% | ||
| 3 months | -18.10% | ||
| 6 months | -43.43% | ||
| Current year | -40.60% |
1 week
14.57
15.95
1 month
14.5718.79
Current year
13.7326.19
1 year
13.7338.23
3 years
13.7338.23
5 years
13.7361.00
10 years
13.7361.00
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Xia Kong
CEO | Chief Executive Officer | 42 | 21-05-16 |
Jing Wang
DFI | Director of Finance/CFO | 37 | 21-05-16 |
Ting Zhu
BRD | Director/Board Member | 35 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bin Wu
BRD | Director/Board Member | 64 | 22-10-09 |
Jiang Feng Liu
BRD | Director/Board Member | 45 | 21-05-16 |
Lan Hao
BRD | Director/Board Member | 56 | 21-05-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 15.07 | +2.87% | 1,466,340 |
| 24-06-06 | 14.65 | -5.54% | 1,834,176 |
| 24-06-05 | 15.51 | -2.02% | 990,480 |
| 24-06-04 | 15.83 | -1.31% | 1,386,420 |
End-of-day quote Shenzhen S.E., June 06, 2024
More quotes
Zhejiang Wecome Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of modern Chinese medicine and western medicine. The Company's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The Company mainly conducts its businesses in the China market.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.60% | 295M | |
| +48.39% | 779B | |
| +40.47% | 631B | |
| -6.13% | 354B | |
| +20.61% | 333B | |
| +10.00% | 301B | |
| +16.67% | 249B | |
| -1.72% | 216B | |
| +10.89% | 214B | |
| +5.80% | 163B |
- Stock Market
- Equities
- 300878 Stock
